Retatrutide lowers A1C and weight more than Ozempic 2 mg in phase 3 head-to-head topline

Tento záznam sa zobrazuje v angličtine, kým nebude aktualizovaný jeho preklad.

Lilly reported topline results from TRANSCEND-T2D-2, an open-label phase 3 trial comparing two doses of investigational retatrutide with Ozempic (semaglutide) 2 mg in 1,298 adults with type 2 diabetes. At 80 weeks, A1C fell by 2.2% with both retatrutide doses versus 1.8% with Ozempic, and body weight fell by 19.5% and 20.9% versus 9.4%, in an estimate that assumes participants stayed on treatment; the A1C superiority test for the lower dose was not controlled for multiple comparisons. Adverse events led 4.8% and 7.9% of retatrutide participants to stop treatment versus 2.7% on Ozempic, and dysesthesia (abnormal skin sensation) affected 4.8% and 6.5% versus 2.7%. The results are company-reported and not yet peer reviewed, and retatrutide remains unapproved.

Zdroje

  1. 01Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial(otvorí zdroj na novej karte) Eli Lilly and Company via PR Newswire
  2. 02Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)(otvorí zdroj na novej karte) ClinicalTrials.gov

Dotknuté peptidy

  1. V klinických štúdiáchRetatrutideTrojitý agonista receptorov GIP, GLP-1 a glukagónu39 Zakázané WADA
  2. SchválenéSemaglutideAgonista receptora GLP-131